Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Silence Therapeutics (DE:XRP2)
FRANKFURT:XRP2
Silence Therapeutics (XRP2) Stock Price & Analysis
4 Followers
XRP2 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€4.48 - €26.80
Previous Close€18.5
Volume0.00
Average Volume (3M)208.00
Market Cap
€882.62M
Enterprise Value€874.03M
Total Cash (Recent Filing)£71.14M
Total Debt (Recent Filing)£63.93M
Price to Earnings (P/E)―
Beta-0.13
Next Earnings
Sep 12, 2024EPS Estimate
-€0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding36,747,555
10 Day Avg. Volume0
30 Day Avg. Volume208
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)N/A
Price to Sales (P/S)75.43
Price to Cash Flow (P/CF)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€56.47Price Target Upside205.26% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Silence Therapeutics News
PremiumCompany Announcements
Silence Therapeutics’ Divesiran Shows Promise in PV Study
PremiumCompany Announcements
Silence Therapeutics Secures $2M Milestone Payment
PremiumCompany Announcements
Silence Therapeutics’ Zerlasiran Shows Promising ResultsBulls Say, Bears Say
Bulls Say
Clinical TrialsAnalyst expects a positive outcome from the Phase 1 trial data for divesiran, which could support the program's advancement to Phase 2.
Management CommentaryManagement's favorable commentary on promising unblinded Divesiran data suggests potential for positive market impact.
Market PotentialIf approved, peak potential revenues for divesiran could surpass $1 billion, with further upside potential if symptom improvement is demonstrated.
Bears Say
Clinical DevelopmentRisks include clinical development, competition, novel modality, commercialization, reimbursement, pricing, business development, and clinical trial risks due to the war in Eastern Europe.
Market CompetitionCompetitive PV landscape with five key assets at different stages of development implies a challenging market entry.
Safety/TolerabilityPV treatments for high-risk patients carry safety/tolerability risks, which may limit their use.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00%
Insiders
0.05% Mutual Funds
53.77% Other Institutional Investors
46.18% Public Companies and
Individual Investors
XRP2 FAQ
What was Silence Therapeutics’s price range in the past 12 months?
Silence Therapeutics lowest stock price was €4.48 and its highest was €26.80 in the past 12 months.
What is Silence Therapeutics’s market cap?
Currently, no data Available
When is Silence Therapeutics’s upcoming earnings report date?
Silence Therapeutics’s upcoming earnings report date is Sep 12, 2024 which is in 57 days.
How were Silence Therapeutics’s earnings last quarter?
Silence Therapeutics released its earnings results on May 16, 2024. The company reported -€0.017 earnings per share for the quarter, beating the consensus estimate of -€0.114 by €0.098.
Is Silence Therapeutics overvalued?
According to Wall Street analysts Silence Therapeutics’s price is currently Undervalued.
Does Silence Therapeutics pay dividends?
Silence Therapeutics does not currently pay dividends.
What is Silence Therapeutics’s EPS estimate?
Silence Therapeutics’s EPS estimate is -€0.11.
How many shares outstanding does Silence Therapeutics have?
Silence Therapeutics has 46,659,940 shares outstanding.
What happened to Silence Therapeutics’s price movement after its last earnings report?
Silence Therapeutics reported an EPS of -€0.017 in its last earnings report, beating expectations of -€0.114. Following the earnings report the stock price went up 5.405%.
Which hedge fund is a major shareholder of Silence Therapeutics?
Among the largest hedge funds holding Silence Therapeutics’s share is Duquesne Family Office LLC. It holds Silence Therapeutics’s shares valued at 8M.
---
Silence Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€56.47 (205.26% Upside)
€56.47 (205.26% Upside)
Blogger Sentiment
Bullish
DE:XRP2 Sentiment 100%
Sector Average 71%
Sector Average 71%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
238.53%
12-Months-Change
Fundamentals
Return on Equity
-49.39%
Trailing 12-Months
Asset Growth
110.51%
Trailing 12-Months
Company Description
Silence Therapeutics
Silence Therapeutics PLC is one of the leading companies in the ribonucleic acid (RNA) technology field. The United Kingdom-based firm researches and develops therapeutics to combat highly unmet medical needs. Its patented RNA interference platform, known as AtuRNAi is employed in vaccines to correct genetic deficiencies and infectious diseases by silencing or replacing the expression of virtually any gene in the genome, modulating expression up as well as down in a variety of organs and cell types. Its technology is currently in the clinic, in a Phase 2a pancreatic cancer trial and its income consists of license fees, milestone and option payments, grant income and fees from research and development collaborations.
---
XRP2 Stock 12 Month Forecast
Average Price Target
€56.47
▲(205.26% Upside)
Technical Analysis
Silence Therapeutics
―
Moderna
―
Gilead Sciences
―
Arrowhead Pharmaceuticals
―
Crispr Therapeutics AG
―
Best Analysts Covering XRP2
1 Year
1 Year Success Rate
4/9 ratings generated profit
1 Year Average Return
+35.33%
reiterated a buy rating 20 days ago
Copying Keay Nakae's trades and holding each position for 1 Year would result in 44.44% of your transactions generating a profit, with an average return of +35.33% per trade.
---